AI-Designed Drug AH-001 Completes U.S. Phase I Trial, Demonstrating Excellent Safety and Tolerability

AH-001, an AI-designed topical protein degrader, has successfully completed the U.S. Phase I clinical trial, demonstrating excellent safety and tolerability at all dose levels with no drug-related adverse events reported157.

The drug is developed by AnHorn Medicines using generative AI and is intended for the treatment of androgenetic alopecia (male pattern hair loss)15.

AH-001 targets the androgen receptor locally through topical application using a novel protein degradation mechanism, addressing the root cause of hair loss and avoiding systemic side effects common with oral hormonal inhibitors like finasteride15.

This is the first AI-designed drug developed in Taiwan to complete a U.S. human clinical trial, highlighting the clinical viability and precision design capability of AnHorn's proprietary AI platform157.

Completion of the Phase I trial sets the stage for Phase II trials focused on dose optimization and efficacy, with plans for global partnerships to further advance the therapy1.

AnHorn Medicines’ AIMCADD platform integrates generative AI and molecular simulation for rapid, precise drug discovery and development, signaling a transformative shift in how drugs are designed1.

Sources:

1. https://www.prnewswire.com/news-releases/ai-designed-drug-ah-001-complete-us-phase-i-trial-demonstrating-excellent-safety-and-tolerability-302598644.html

5. https://trial.medpath.com/news/40e14569f4b8e223/anhorn-medicines-ai-designed-hair-loss-drug-ah-001-completes-phase-i-trial-with-excellent-safety-profile

7. https://aicompetence.org/ai-designed-drug-ah-001-complete-u-s-phase-i-trial-demonstrating-excellent-safety-and-tolerability/